Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, Bengrine L, Bellio H, Bertaut A, Hampe L, Daumoine S, Rederstorff E, Peroz M, Huppe T, Derangère V, Rageot D, Simard J, Truntzer C, Fumet JD, Ghiringhelli F.
Thibaudin M, et al. Among authors: vincent j.
Signal Transduct Target Ther. 2025 Jan 17;10(1):22. doi: 10.1038/s41392-024-02116-4.
Signal Transduct Target Ther. 2025.
PMID: 39820336
Clinical Trial.